These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22170488)

  • 1. Aldo-keto reductase 1C3 is expressed in differentiated human epidermis, affects keratinocyte differentiation, and is upregulated in atopic dermatitis.
    Mantel A; Carpenter-Mendini AB; Vanbuskirk JB; De Benedetto A; Beck LA; Pentland AP
    J Invest Dermatol; 2012 Apr; 132(4):1103-10. PubMed ID: 22170488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
    Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
    J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
    Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
    Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids.
    Mantel A; Newsome A; Thekkudan T; Frazier R; Katdare M
    Exp Dermatol; 2016 Jan; 25(1):38-43. PubMed ID: 26308156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
    Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
    Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival.
    Marín YE; Seiberg M; Lin CB
    Exp Dermatol; 2009 Jul; 18(7):611-8. PubMed ID: 19320734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
    Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
    Xie L; Yu J; Guo W; Wei L; Liu Y; Wang X; Song X
    Cancer Gene Ther; 2013 Apr; 20(4):260-6. PubMed ID: 23519145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
    Wang S; Yang Q; Fung KM; Lin HK
    Mol Cell Endocrinol; 2008 Jul; 289(1-2):60-6. PubMed ID: 18508192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
    Byrns MC; Mindnich R; Duan L; Penning TM
    J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
    Byrns MC; Penning TM
    Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
    Zhong T; Xu F; Xu J; Liu L; Chen Y
    Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
    Byrns MC; Steckelbroeck S; Penning TM
    Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
    Azzarello JT; Lin HK; Gherezghiher A; Zakharov V; Yu Z; Kropp BP; Culkin DJ; Penning TM; Fung KM
    Int J Clin Exp Pathol; 2009 Nov; 3(2):147-55. PubMed ID: 20126582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
    Park AL; Lin HK; Yang Q; Sing CW; Fan M; Mapstone TB; Gross NL; Gumerlock MK; Martin MD; Rabb CH; Fung KM
    Int J Clin Exp Pathol; 2010 Mar; 3(8):743-54. PubMed ID: 21151387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
    Byrns MC; Jin Y; Penning TM
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis.
    Nakamura Y; Hornsby PJ; Casson P; Morimoto R; Satoh F; Xing Y; Kennedy MR; Sasano H; Rainey WE
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2192-8. PubMed ID: 19336506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.